SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
12-Mar-19 4:58 PM View: | Broadwood Partners Lp | Asterias Biotherapeutics, I... (NONE) | 08-Mar-19 | Disposition (other) | 5,292,160 | -- | -- | (100%) 5.29M to 0 | |
12-Mar-19 4:58 PM View: | Broadwood Partners Lp | Asterias Biotherapeutics, I... (NONE) | 08-Mar-19 | Disposition (other) | -- | -- | -- | 0% -- | |
05-Mar-19 4:32 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 01-Mar-19 | Payment of Exercise | 48,826 | $0.95 | $46,384.70 | (15%) 316.02K to 267.19K | |
05-Mar-19 4:30 PM View: | Chavez Ryan Daniel CFO and General Counsel | Asterias Biotherapeutics, I... (NONE) | 01-Mar-19 | Payment of Exercise | 44,471 | $0.95 | $42,247.40 | (15%) 299.98K to 255.51K | |
05-Mar-19 4:31 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 01-Mar-19 | Payment of Exercise | 76,588 | $0.95 | $72,758.60 | (22%) 350.21K to 273.62K | |
05-Mar-19 4:32 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 01-Mar-19 | Grant | 156,452 | -- | -- | 98% 159.57K to 316.02K | |
05-Mar-19 4:31 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 01-Mar-19 | Grant | 252,606 | -- | -- | 259% 97.6K to 350.21K | |
05-Mar-19 4:30 PM View: | Chavez Ryan Daniel CFO and General Counsel | Asterias Biotherapeutics, I... (NONE) | 01-Mar-19 | Grant | 145,263 | -- | -- | 94% 154.72K to 299.98K | |
04-Jan-19 5:02 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 02-Jan-19 | Payment of Exercise | 20,440 | $0.68 | $13,899.20 | (11%) 180.01K to 159.57K | |
04-Jan-19 5:05 PM View: | Chavez Ryan Daniel CFO and General Counsel | Asterias Biotherapeutics, I... (NONE) | 02-Jan-19 | Payment of Exercise | 20,440 | $0.68 | $13,899.20 | (12%) 175.16K to 154.72K | |
29-Aug-18 8:02 AM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 27-Aug-18 | Purchase | 3,141 | $1.59 | $4,999.84 | 3% 94.46K to 97.6K | |
27-Jul-18 4:00 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 25-Jul-18 | Purchase | 2,950 | $1.69 | $4,999.96 | 3% 91.51K to 94.46K | |
27-Jun-18 7:03 AM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 25-Jun-18 | Purchase | 3,067 | $1.63 | $4,999.21 | 3% 88.45K to 91.51K | |
31-May-18 5:00 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 25-May-18 | Purchase | 3,153 | $1.59 | $4,999.71 | 4% 85.29K to 88.45K | |
27-Apr-18 4:33 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 25-Apr-18 | Purchase | 3,752 | $1.33 | $4,990.16 | 5% 81.54K to 85.29K | |
30-Mar-18 4:58 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 30-Mar-18 | Payment of Exercise | 6,483 | $1.45 | $9,400.35 | (3%) 186.49K to 180.01K | |
30-Mar-18 4:54 PM View: | Chavez Ryan Daniel CFO and General Counsel | Asterias Biotherapeutics, I... (NONE) | 30-Mar-18 | Payment of Exercise | 6,483 | $1.45 | $9,400.35 | (4%) 181.64K to 175.16K | |
28-Mar-18 5:00 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 26-Mar-18 | Purchase | 2,839 | $1.76 | $4,996.64 | 4% 78.7K to 81.54K | |
19-Mar-18 6:58 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 15-Mar-18 | Grant | 124,000 | -- | -- | 56% 220.35K to 344.35K | |
19-Mar-18 6:58 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 15-Mar-18 | Payment of Exercise | 22,686 | $1.95 | $44,237.70 | (7%) 344.35K to 321.67K | |
19-Mar-18 6:52 PM View: | Chavez Ryan Daniel CFO and General Counsel | Asterias Biotherapeutics, I... (NONE) | 15-Mar-18 | Payment of Exercise | 21,633 | $1.95 | $42,184.40 | (6%) 337.84K to 316.2K | |
19-Mar-18 7:03 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 15-Mar-18 | Grant | 94,872 | -- | -- | 778% 12.19K to 107.06K | |
19-Mar-18 6:52 PM View: | Chavez Ryan Daniel CFO and General Counsel | Asterias Biotherapeutics, I... (NONE) | 15-Mar-18 | Grant | 118,708 | -- | -- | 54% 219.13K to 337.84K | |
19-Mar-18 7:03 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 15-Mar-18 | Payment of Exercise | 28,358 | $1.95 | $55,298.10 | (26%) 107.06K to 78.7K | |
28-Feb-18 4:21 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 26-Feb-18 | Purchase | 2,255 | $2.22 | $4,999.79 | 23% 9.93K to 12.19K | |
26-Jan-18 4:01 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 25-Jan-18 | Purchase | 2,134 | $2.34 | $4,999.96 | 27% 7.8K to 9.93K | |
28-Dec-17 7:41 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 26-Dec-17 | Purchase | 2,247 | $2.22 | $4,988.34 | 40% 5.55K to 7.8K | |
29-Nov-17 4:01 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 27-Nov-17 | Purchase | 2,076 | $2.41 | $5,003.16 | 60% 3.48K to 5.55K | |
27-Oct-17 4:00 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 25-Oct-17 | Purchase | 1,939 | $2.55 | $4,944.45 | 126% 1.54K to 3.48K | |
18-Oct-17 5:34 PM View: | Broadwood Partners Lp | Asterias Biotherapeutics, I... (NONE) | 16-Oct-17 | Purchase | -- | -- | -- | 0% 10.58M | |
18-Oct-17 5:34 PM View: | Broadwood Partners Lp | Asterias Biotherapeutics, I... (NONE) | 16-Oct-17 | Purchase | 1,592,310 | $2.60 | $4,140,000.00 | 18% 8.99M to 10.58M | |
27-Sep-17 2:04 PM View: | Mulroy Michael H. President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 25-Sep-17 | Purchase | 1,537 | $3.25 | $4,996.79 | 100% 0 to 1.54K | |
07-Jun-17 4:30 PM View: | Spink Katharine E. EVP & COO | Asterias Biotherapeutics, I... (NONE) | 05-Jun-17 | Payment of Exercise | 7,260 | $3.20 | $23,232.00 | (40%) 18.21K to 10.95K | |
07-Jun-17 4:30 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 05-Jun-17 | Payment of Exercise | 6,745 | $3.20 | $21,584.00 | (7%) 91.92K to 85.18K | |
07-Jun-17 4:30 PM View: | Lebkowski Jane Chief Scientific Officer | Asterias Biotherapeutics, I... (NONE) | 05-Jun-17 | Payment of Exercise | 7,015 | $3.20 | $22,448.00 | (6%) 110.01K to 102.99K | |
03-Apr-17 5:03 PM View: | Chavez Ryan Daniel CFO and General Counsel | Asterias Biotherapeutics, I... (NONE) | 30-Mar-17 | Grant | 84,565 | -- | -- | 884% 9.56K to 94.13K | |
03-Apr-17 5:06 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 30-Mar-17 | Grant | 91,922 | -- | -- | 543% 16.92K to 108.84K | |
03-Apr-17 5:03 PM View: | Cartt Stephen Lahue President and CEO Director | Asterias Biotherapeutics, I... (NONE) | 30-Mar-17 | Grant | 32,783 | -- | -- | 13% 260.0K to 292.78K | |
03-Apr-17 4:59 PM View: | Spink Katharine E. Chief Operating Officer | Asterias Biotherapeutics, I... (NONE) | 30-Mar-17 | Grant | 18,209 | -- | -- | 100% 0 to 18.21K | |
03-Apr-17 5:01 PM View: | Lebkowski Jane President of R&D | Asterias Biotherapeutics, I... (NONE) | 30-Mar-17 | Grant | 92,670 | -- | -- | 177% 52.34K to 145.01K | |
11-Jan-17 4:30 PM View: | Lebkowski Jane President of R&D | Asterias Biotherapeutics, I... (NONE) | 09-Jan-17 | Payment of Exercise | 2,537 | -- | -- | (13%) 19.87K to 17.34K | |
11-Jan-17 4:30 PM View: | Spink Katharine E. Chief Operating Officer | Asterias Biotherapeutics, I... (NONE) | 09-Jan-17 | Sale (Planned) | 4,781 | $4.60 | $22,006.90 | (100%) 4.78K to 0 | |
11-Jan-17 4:30 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 09-Jan-17 | Sale (Planned) | 3,415 | $4.60 | $15,719.20 | (100%) 3.42K to 0 | |
11-Jan-17 4:30 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 09-Jan-17 | Payment of Exercise | 2,056 | -- | -- | (38%) 5.47K to 3.42K | |
11-Jan-17 4:30 PM View: | Spink Katharine E. Chief Operating Officer | Asterias Biotherapeutics, I... (NONE) | 09-Jan-17 | Payment of Exercise | 2,878 | -- | -- | (38%) 7.66K to 4.78K | |
06-Jan-17 5:15 PM View: | Spink Katharine E. Chief Operating Officer | Asterias Biotherapeutics, I... (NONE) | 27-Dec-16 | Option Exercise | 2,500 | $2.34 | $5,850.00 | 100% 0 to 2.5K | |
06-Jan-17 5:15 PM View: | Spink Katharine E. Chief Operating Officer | Asterias Biotherapeutics, I... (NONE) | 27-Dec-16 | Planned Option Sale | 2,500 | $5.00 | $12,500.00 | (100%) 2.5K to 0 | |
06-Jan-17 5:13 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 27-Dec-16 | Option Exercise | 2,500 | $2.34 | $5,850.00 | 100% 0 to 2.5K | |
06-Jan-17 5:13 PM View: | Wirth Edward Chief Medical Officer | Asterias Biotherapeutics, I... (NONE) | 27-Dec-16 | Planned Option Sale | 2,500 | $5.00 | $12,500.00 | (100%) 2.5K to 0 | |
28-Nov-16 4:30 PM View: | Spink Katharine E. Chief Operating Officer | Asterias Biotherapeutics, I... (NONE) | 23-Nov-16 | Option Exercise | 2,500 | $2.34 | $5,850.00 | 100% 0 to 2.5K |